Trials / Completed
CompletedNCT02122822
Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Cure&Sure Biotech Co., LTD · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This trial is studying the safety and effectiveness of autologous gp96 treatment of glioblastoma and to see how well it works in treating patients with newly diagnosed supratentoria glioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | gp96 | vaccination of autologous gp96 derived from tumor tissue + basal treatment |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2015-07-01
- Completion
- 2017-05-01
- First posted
- 2014-04-25
- Last updated
- 2017-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02122822. Inclusion in this directory is not an endorsement.